NCT06745804 - Study of 68Ga-R10602 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma

Interventions

DRUG

68Ga-R10602 injection

68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer

Trial Locations (6)

46202

RECRUITING

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

48109

RECRUITING

University of Michigan Medicine, Ann Arbor

52242

RECRUITING

University of Iowa, Iowa City

77030

RECRUITING

MD Anderson Cancer Center, Houston

90095

RECRUITING

UCLA Department of Medicine - Hematology/Oncology, Los Angeles

844112

RECRUITING

University of Utah, Huntsman Cancer Institute, Salt Lake City